AppRiver’s Balkwell Tapped to Lead European Channel Sales Efforts
AppRiver, a Zix (NASDAQ: ZIXI) company and leading channel-first provider of security, productivity, and compliance solutions, recently announced that Paul Balkwell, senior director of channel sales in the United Kingdom and Ireland, will now lead the company’s channel sales efforts across all of Europe.
Balkwell, who joined AppRiver in 2018, will lead teams that oversee the rapid expansion of AppRiver’s Indirect Cloud Solution Provider (CSP) Program which will offer Microsoft Office 365 alongside AppRiver’s suite of world-class cybersecurity solutions that help businesses protect against security threats and meet compliance standards, such as the General Data Protection Regulation (GDPR).
Balkwell brings more than two decades of leadership experience in driving technology sales and partner programs. According to Chris Essex, AppRiver’s senior vice president of global sales, he is also a self-starter with the ability to motivate and inspire individuals and teams to perform at the next level.
“Paul has a proven reputation for successfully competing in new markets and driving strong revenue growth. He has helped MSPs in the UK understand the value of AppRiver’s Phenomenal Care and advanced security solutions while expanding our channel,” Essex said. “Paul’s deep understanding of the European market combined with his knowledge of AppRiver’s security and productivity solutions for business make him the perfect choice to continue AppRiver’s rapid global growth.”
Balkwell believes the acquisition of AppRiver by Zix brings together two very powerful cybersecurity brands that will deliver to partners a unique value proposition based on providing Office 365 as well as the proprietary solutions necessary to fully protect their customers.
“I look forward to leading our AppRiver/Zix Channel Sales team in UK and Europe, bringing new capabilities and solutions to resellers that are hungry for new revenue streams and more effective ways to keep their customers safe,” Balkwell said.
AppRiver, a Zix company, is a channel-first provider of cloud-enabled security and productivity services, with a 4,500-strong reseller community that protects 60,000 companies worldwide against a growing list of dangerous online threats. Among the world’s top Office 365 and Secure Hosted Exchange providers, the company’s brand is built on highly effective security services backed by 24/7 white-glove Phenomenal Care® customer service. AppRiver is headquartered in Gulf Breeze, Florida and maintains offices in Georgia, Texas, New York, Canada, Switzerland, and the U.K. For more information, please visit www.appriver.com.
About Zix Corporation
Zix Corporation (Zix) is a leader in email security. Trusted by the nation’s most influential institutions in healthcare, finance and government, Zix delivers a superior experience and easy-to-use solutions for email encryption and data loss prevention, advanced threat protection, unified information archiving and bring your own device (BYOD) mobile security. Focusing on the protection of business communication, Zix enables its customers to better secure data and meet compliance needs. Zix is publicly traded on the Nasdaq Global Market under the symbol ZIXI. For more information, visit www.zixcorp.com.
AppRiver Company Contact
Zix Investor Contact
Matt Glover and Najim Mostamand, CFA
Liolios Group, Inc.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CES Unveiled in Amsterdam to Showcase Tech for Good19.8.2019 07:00:00 CEST | Press release
Consumer Technology Association (CTA): WHAT: The Consumer Technology Association (CTA)® today announced several government officials, dignitaries and industry leaders attending CES Unveiled in Amsterdam, an official CES preview event, focusing on the theme “Tech for Good.” Returning for its third year, CES Unveiled in Amsterdam will bring together executives, influential media, prominent industry influencers, and more than 100 companies (including 50+ startups) to explore the latest technology trends and innovations from the Netherlands and surrounding European countries leading up to CES® 2020. Attendees and media are able to register for CES Unveiled in Amsterdam online. WHO: Government officials and dignitaries including Mona Keijzer, Netherlands State Secretary for Economic Affairs and Climate Policy; HRH Prince Constantijn van Oranje, Special Envoy at TechLeap.NL; and Pete Hoekstra, U.S. Ambassador to the Netherlands, will share insights on emerging trends in the industry, includi
RISO Unveils VALEZUS, a New Brand for the Production-printing Market19.8.2019 06:00:00 CEST | Press release
RISO KAGAKU CORPORATION (President & CEO: Akira Hayama; hereinafter “RISO”) announced today the launch of VALEZUS, a new brand of high-speed ink-jet printers for the production-printing market. RISO will start with successive rollouts worldwide of the new brand’s first product, the VALEZUS T2100, a high-speed, 320-page-per-minute (320-ppm) cut-sheet printer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190818005001/en/ 1 The new brand, VALEZUS One of RISO’s commanding strengths is the development of inks optimized for high-speed paper feeding and high-speed printing. This expertise enables RISO to deliver unique printing solutions serving the demand for high-volume printing. With technologies developed and cultivated in this field, RISO launches the VALEZUS, a fresh brand targeting the production-printing market. 2 The all-new VALEZUS T2100 VALEZUS T2100 The first product of the new brand, the VALEZUS T2100 is a high-speed
Velodyne Files Patent Infringement Complaint with ITC Against Hesai and RoboSense16.8.2019 12:00:00 CEST | Press release
Velodyne Lidar, Inc. filed a patent infringement complaint with the U.S. International Trade Commission (ITC) against Hesai Photonics Technology Co., Ltd. and Suteng Innovation Technology Co., Ltd. (a.k.a. RoboSense) for violations of section 337 of the Tariff Act of 1930 which makes unfair methods of competition and importation of certain products into the United States unlawful. Earlier this week, Velodyne also filed patent infringement complaints against Hesai and RoboSense in the U.S. District Court for the Northern District of California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005041/en/ Velodyne Lidar’s Alpha Puck™, Ultra Puck™ and Puck™ surround view sensors (left to right). (Photo: Business Wire) Velodyne is asking the ITC to investigate these lidar manufacturers for unlawfully importing and selling lidar sensors that infringe Velodyne’s patented lidar technology (U.S. Patent 7,969,558). Velodyne reques
Merz Announces Key Governance Changes16.8.2019 09:26:00 CEST | Press release
Merz, a global leader in medical aesthetics and specialty neurology, announced today that Philip Burchard will be appointed Chairman of the company’s Shareholders Council. He will assume this role in addition to his current position as Chief Executive Officer of the Merz Healthcare Group. In his new position, Philip Burchard will succeed Andreas Krebs, who has decided to step down from his current roles as Chairman of the Shareholders Council and Supervisory Board of Merz in order to dedicate more time to his personal entrepreneurial and philanthropic activities. In addition, Dr. Christian Holzherr will be the new Chairman of the Merz Supervisory Board. All changes will be effective as of October 31, 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005106/en/ Philip Burchard, CEO of Merz (Photo: Business Wire) Philip Burchard joined Merz as CEO in July 2012. Under his leadership, Merz has focused its strategy on ae
FINEOS lists on the Australian Securities Exchange16.8.2019 07:22:00 CEST | Press release
FINEOS Corporation Holdings plc (ASX:FCL), a leading provider of group and individual core systems for life, accident and health insurance, today announced the commencement of trading on the Australian Securities Exchange (ASX) via an initial public offering (IPO). The total number of securities (CHESS Depository Interests or “CDIs”) on offer was 84.4 million at a price of A$2.50 per CDI. Total gross proceeds from the offer amounted to A$211 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005058/en/ FINEOS lists on the Australian Securities Exchange (Photo: Business Wire) FINEOS intends to use the net proceeds from the IPO to invest further in R&D to grow the FINEOS product footprint and develop new business lines, to invest in additional sales, marketing and client account management capabilities and to pay down existing debt and shareholders selling down. Key areas of growth strategy for FINEOS include: • Inc
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis15.8.2019 20:01:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis (RA) has been validated and is now under evaluation by the European Medicines Agency (EMA). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190815005605/en/ “We are excited about the validation of this application which is an important milestone in our ongoing work to improve the lives of people living with rheumatoid arthritis and other inflammatory conditions,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences. The MAA for filgotinib is supported by 24-week data from the Phase 3 FINCH clinical trials in which once-daily treatment with filgotinib achieved improvements in clinical signs and symptoms, achievem